Welcome Guest!  Login | Register | Help
Home News Screener Maps Groups Portfolio Insider Futures Forex Collaborate Store Elite
Settings
BMY [NYSE]
Bristol-Myers Squibb Company
IndexS&P 500 P/E31.68 EPS (ttm)1.55 Insider Own0.10% Shs Outstand1.66B Perf Week-2.89%
Market Cap81.37B Forward P/E29.41 EPS next Y1.67 Insider Trans18.53% Shs Float1.65B Perf Month-9.64%
Income2.56B PEG2.21 EPS next Q0.45 Inst Own70.90% Short Float1.44% Perf Quarter-9.26%
Sales16.39B P/S4.97 EPS this Y32.80% Inst Trans-0.02% Short Ratio2.53 Perf Half Y5.07%
Book/sh9.18 P/B5.35 EPS next Y-6.07% ROA6.90% Target Price55.12 Perf Year23.89%
Cash/sh2.73 P/C17.98 EPS next 5Y14.33% ROE17.70% 52W Range38.06 - 57.09 Perf YTD-6.95%
Dividend1.44 P/FCF116.41 EPS past 5Y-3.60% ROI10.70% 52W High-13.97% Beta0.47
Dividend %2.93% Quick Ratio1.40 Sales past 5Y-1.50% Gross Margin71.80% 52W Low29.05% ATR1.24
Employees28000 Current Ratio1.50 Sales Q/Q6.00% Oper. Margin19.70% RSI (14)39.46 Volatility2.47% 2.63%
OptionableYes Debt/Eq0.55 EPS Q/Q-21.40% Profit Margin15.60% Rel Volume0.82 Prev Close48.17
ShortableYes LT Debt/Eq0.53 EarningsApr 29 BMO Payout89.70% Avg Volume9.38M Price49.11
Recom2.30 SMA20-3.34% SMA50-6.11% SMA2000.87% Volume7,649,940 Change1.95%
15-Jan-14Reiterated Argus Buy $58 → $62
10-Jan-14Upgrade Barclays Equal Weight → Overweight $52 → $65
20-Dec-13Reiterated UBS Neutral $48 → $54
29-Jul-13Reiterated Argus Buy $54
17-Jul-13Reiterated Barclays Equal Weight $42 → $45
04-Jun-13Reiterated Argus Buy $46 → $54
26-Apr-13Reiterated MKM Partners Sell $26 → $29
15-Apr-13Reiterated Barclays Equal Weight $33 → $42
25-Jan-13Reiterated UBS Neutral $34 → $36
09-Jan-12Reiterated Barclays Capital Overweight $34 → $36
19-Oct-11Initiated MKM Partners Sell $26
27-Jun-11Reiterated UBS Neutral $28 → $30
31-Mar-11Downgrade Jefferies Buy → Hold $28.50
28-Mar-11Reiterated Barclays Capital Overweight $28 → $30
22-Sep-10Reiterated Deutsche Bank Buy $28 → $31.50
01-Sep-10Reiterated UBS Neutral $26 → $27
31-Aug-10Upgrade Jefferies Hold → Buy $28.80 → $30
12-Mar-10Initiated Jefferies & Co Hold $27
16-Dec-09Initiated UBS Neutral
09-Oct-09Initiated Wells Fargo Outperform
16-Apr-14 05:30AM  Reckitt leans towards pharmaceuticals spin-off Reuters
15-Apr-14 05:40PM  Bristol-Myers Seeks Approval for HIV Combo Drug Zacks
03:30PM  Portola's Betrixaban Study Design Published Zacks
02:56PM  This Forgotten Pharma Could Be a Hit for Your Portfolio at Motley Fool
02:05PM  Finding Attractive Yields in Financials, IT and Health Care: A Wall Street Transcript Interview with Kenneth M. Conrad, Ph.D., CFA, a Portfolio Manager at BMO Global Asset Management for the BMO Custom Quantitative Solutions Group Wall Street Transcript
09:40AM  Can Merck & Co. Inc. and Bristol-Myers Squibb Co. Dethrone Gilead Sciences Inc. for Hep C Combo? at Motley Fool
06:05AM  Boehringer 2013 profit up on Pradaxa sales, cost cuts Reuters
14-Apr-14 06:14PM  Amgen's Conundrum at Motley Fool
09:30AM  Hedge Funds Love These 3 Pharma Stocks StreetAuthority Network
08:07AM  Can Merck, Bristol-Myers, or AbbVie Compete with Gileads Cure for Hepatitis C? at Wall St. Cheat Sheet
08:00AM  Bristol-Myers Squibb Submits New Drug Application to U.S. FDA for a Fixed-Dose Combination Tablet of Atazanavir Sulfate with Cobicistat for People Living with HIV-1 Business Wire
12-Apr-14 01:02AM  Merck Shouts "Me, Too!" But Will It Matter? at Motley Fool
11-Apr-14 10:30AM  Encouraging Data from Bristol-Myers Zacks
10-Apr-14 03:36PM  Stunning Spending Growth Prediction for Hepatitis C at Motley Fool
03:30PM  Merck Up on Encouraging HCV Data Zacks
10:36AM  Gilead Sciences: How Big a Threat is Merck? at Barrons.com
08:46AM  Today's Biotech Stocks to Watch: Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Inc. at Motley Fool
08:01AM  [$$] Bristol-Myers Reports Positive Results from Hepatitis C Drug Study at The Wall Street Journal
07:00AM  Bristol-Myers Squibb Presents Phase III Data Demonstrating that Investigational All-oral Daclatasvir and Asunaprevir Therapy Achieved SVR12 Rates of up to 90% Among Broad Range of Genotype 1b Hepatitis C Patients Business Wire
09-Apr-14 05:30PM  Oncolytics Reports Additional Data on Reolysin Zacks
11:43AM  Gilead defended by analysts after recent pullback at theflyonthewall.com
10:50AM  Positive Trial Data Lifts Alkermes Zacks
08:32AM  Express Scripts Trying To Shame Gilead Into Reducing Sovaldi Price: Who Is Really The Greedy One? at Seeking Alpha
07:00AM  WHO joins clamour to make new hepatitis C pills affordable Reuters
08-Apr-14 11:23AM  Healthcare Investors Suffering Losses While Drug-Pricing War Rages at TheStreet
10:40AM  Bristol-Myers Seeks FDA Approval for HCV Candidates Zacks
07-Apr-14 11:59AM  Boehringer Ingelheim's Oral Anticoagulant Gains New Indication at Forbes
11:17AM  The Growth Rout: With Amazon, Google on the Ropes, Buy Bristol Myers, Mead Johnson Instead at Barrons.com
08:00AM  Bristol-Myers Squibb Submits NDAs for Daclatasvir and Asunaprevir to US FDA for the Treatment of Hepatitis C Business Wire
06-Apr-14 05:01AM  AbbVie - Strong Product Pipeline Is Defining Its Future at Seeking Alpha
04-Apr-14 09:31AM  3 Under-Loved Dividend Darlings for Your Portfolio at Motley Fool
02-Apr-14 11:37PM  Forstmann Little eyes $2bn sale of 24 Hour Fitness chain at Financial Times
04:02AM  GlaxoSmithKline throws in towel on lung cancer vaccine trial Reuters
01-Apr-14 09:00AM  Bristol-Myers Squibb to Announce Results for First Quarter 2014 on April 29 Business Wire
31-Mar-14 02:51PM  [video] Injectable cholesterol drugs to face challenges at CNBC
01:19PM  [video] New class of cholesterol drugs at CNBC
12:03PM  Cramer: Keep an Eye on Celgene (CELG), Gilead (GILD), Isis Pharmaceuticals (ISIS) and Seattle Genetics (SGEN) at TheStreet
29-Mar-14 08:00AM  [video] Jim Cramer Says Keep an Eye on 'New Pharma' as an Investment Theme at TheStreet
28-Mar-14 08:36PM  Don't Give Up On Momentum at Seeking Alpha
04:18PM  New Atrial Fibrillation Guideline Supports New Drugs And Devices at Forbes
01:31PM  Update on Glaxo's Mekinist-Tafinlar Zacks
10:00AM  [video] High drug costs at CNBC
27-Mar-14 08:17AM  Pfizer, Bristol-Myers announce results of subanalysis of Phase 3 ARISTOTLE trial theflyonthewall.com
08:15AM  Sovaldi And The Cost-Innovation Paradox at Forbes
08:15AM  Congress Makes Sovaldi A Scapegoat: The Cost-Innovation Paradox In The US Healthcare System at Forbes
08:15AM  Congress Makes Sovaldi A Scapegoat: The Cost-Innovation Paradox In The U.S. Healthcare System at Forbes
08:14AM  In A Subanalysis, The Benefits Of Eliquis® (apixaban) Vs. Warfarin In Reducing The Risk Of Stroke In Patients With Nonvalvular Atrial Fibrillation Were Consistent, Regardless Of Blood Pressure Control 1 Business Wire
07:14AM  Gilead can defend Sovaldi pricing, says RW Baird theflyonthewall.com
26-Mar-14 11:42AM  Danish drug maker Santaris considers U.S. listing -investor Reuters
08:45AM  J.P. Morgan Says Buy Specialty and Big Pharmaceuticals Now at 24/7 Wall St.
06:00AM  Once Seen As Too Scary, Editing People's Genes With Viruses Makes A $618 Million Comeback at Forbes
06:00AM  Gene Therapy's Big Comeback at Forbes
05:53AM  [$$] Bristol-Myers Still Lags in Hepatitis C at Barrons.com
25-Mar-14 06:23PM  Top Fund Weathers Biotech Stock Sell-Off at Investor's Business Daily
03:45PM  AstraZeneca's Forxiga Approved in Japan Zacks
07:34AM  The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Pfizer, Alexion Pharmaceuticals, Gilead Sciences and AGCO Zacks
24-Mar-14 05:02PM  Biotech Weakness Makes Indices Sick at Minyanville
09:40AM  Stock Market News for March 24, 2014 Zacks
07:51AM  Story Stocks from Briefing.com Briefing.com
07:25AM  Story Stocks from Briefing.com Briefing.com
06:19AM  Bristol-Myers, Roche, working on possible blockbusters for melanoma, WSJ says theflyonthewall.com
05:39AM  Bristol-Myers Squibb to Present Data for Daclatasvir in Multiple Investigational All-oral Combinations across Hepatitis C Genotypes at The International Liver CongressTM Business Wire
23-Mar-14 01:07AM  A Case Of 'He Said, She Said' at Seeking Alpha
22-Mar-14 09:30AM  Can These Companies Bounce Back from Disappointing Sales? at Motley Fool
21-Mar-14 08:51PM  Geron Held Up at Motley Fool
11:25AM  Story Stocks from Briefing.com Briefing.com
09:15AM  Story Stocks from Briefing.com Briefing.com
07:54AM  Story Stocks from Briefing.com Briefing.com
07:47AM  Story Stocks from Briefing.com Briefing.com
20-Mar-14 10:29AM  Story Stocks from Briefing.com Briefing.com
07:31AM  Story Stocks from Briefing.com Briefing.com
19-Mar-14 09:03PM  Bristol-Myers, Sanofi Sued by Hawaii Over Plavix Labeling at Bloomberg
05:55PM  Drug developer Alder BioPharma files for $115M IPO AP
05:28PM  Big Pharma Ramps Up Hep C Strategies Investor's Business Daily
12:35PM  Better Buy: Twitter vs. Bristol-Myers Squibb at Motley Fool
10:33AM  Story Stocks from Briefing.com Briefing.com
09:31AM  Mixed News for Pfizer: A Good Chance to Buy? at Motley Fool
08:02AM  Gilead's HCV Challengers Near The Starting Gate at Investor's Business Daily
07:41AM  Story Stocks from Briefing.com Briefing.com
18-Mar-14 06:31PM  Five Prime, Bristol-Myers Squibb Cut $350M Immuno-Oncology Deal at Motley Fool
11:00AM  Bristol-Myers, Five Prime Join Forces, Shares up Zacks
09:31AM  Does Bristol-Myers Squibb Offer Good Value? at Motley Fool
08:58AM  Story Stocks from Briefing.com Briefing.com
07:46AM  Story Stocks from Briefing.com Briefing.com
17-Mar-14 01:31PM  Why Five Prime Therapeutics Inc. Shares Surged at Motley Fool
12:01PM  Market rookie Five Prime's shares surge on deal with Bristol-Myers at MarketWatch
11:28AM  Bristol-Myers in $50.5M deal with Five Prime AP
11:10AM  [$$] Officials Probe Pilot's Home Flight Simulator at The Wall Street Journal
10:12AM  [$$] Under Armour Approves Stock Split at The Wall Street Journal
09:32AM  Today's Top Biotech Stories: Five Prime, Bristol-Myers Squibb, Intercept, and Gilead Sciences at Motley Fool
09:15AM  Stocks to Watch: Keurig Green Mountain, JA Solar, Five Prime at The Wall Street Journal
08:42AM  Story Stocks from Briefing.com Briefing.com
08:11AM  Innovation Matters Again in the OR: A Wall Street Transcript Interview with Matt Miksic, a Managing Director and Senior Research Analyst at Piper Jaffray & Co., Covering Medical Technology and Hospital Supply Stocks Wall Street Transcript
06:59AM  Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways GlobeNewswire
06:59AM  Five Prime Therapeutics and Bristol-Myers Squibb Sign Collaboration Agreement to Discover Novel Immuno-Oncology Therapies for Two Immune Checkpoint Pathways Business Wire
14-Mar-14 09:55PM  Bristol-Myers Squibb and Pfizer Announce FDA Approval of Eliquis for DVT at Motley Fool
06:31PM  Can AbbVie Continue Its Bull Run? at Motley Fool
05:28PM  Bristol-Myers and Pfizer Win Approval of New Indication for Eliquis at Wall St. Cheat Sheet
01:17PM  Bristol's Eliquis approved to prevent clots after hip, knee surgery Reuters
01:00PM  U.S. FDA Approves Eliquis® (apixaban) To Reduce The Risk Of Blood Clots Following Hip Or Knee Replacement Surgery Business Wire
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecule products, and biologics in various therapeutic areas, including virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; metabolics; immunoscience; and cardiovascular. The company's principal products are virology products comprising Baraclude, Reyataz, and Sustiva; oncology products, including Erbitux, Sprycel, and Yervoy; neuroscience products, such as Abilify; metabolics consisting of Bydureon, Byetta, Forxiga, and Onglyza/Kombiglyze; immunoscience products, including Nulojix and Orencia; and cardiovascular products, such as Avapro/Avalide, Eliquis, and Plavix. It has various products under Phase III clinical trials for the treatment of hepatitis C virus infection, including Asunaprevir; Daclatasvir; BMS-791325; and Peginterferon lambda. The company also has various products under Phase III clinical trials for treatment of cancer comprising Elotuzumab and Nivolumab. In addition, it develops Baraclude and Reyataz for pediatric extensions; Erbitux for esophageal cancer; Yervoy for melanoma, prostate cancer, and non-small-cell and small cell lung cancer; Orencia for lupus nephritis and psoriatic arthritis; and Eliquis for venous thromboembolic treatment and prevention. The company sells its products to wholesalers, and directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. It has strategic alliances with various third parties. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
JUDGE ANN POWELLSVP, Human ResourcesApr 01Option Exercise0.001,55403,693Apr 03 04:17 PM
Caldarella Joseph CSVP & ControllerMar 13Sale55.209,137504,36268,965Mar 13 04:32 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 10Option Exercise0.002,739058,345Mar 12 04:54 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 10Option Exercise0.004,8780262,120Mar 12 04:52 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 10Option Exercise0.001,173037,948Mar 12 04:53 PM
Nielsen AnneChief Compliance & Ethics OffMar 10Option Exercise0.00688043,432Mar 12 04:53 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Option Exercise0.002,739011,600Mar 12 04:53 PM
Cuss Francis MEVP & CSOMar 10Option Exercise0.002,7390239,268Mar 12 04:51 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 10Option Exercise0.002,528092,314Mar 12 04:51 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 10Option Exercise0.001,850049,399Mar 12 04:52 PM
Heller Frances KSVP, Business DevelopmentMar 10Option Exercise0.001,60904,402Mar 12 04:52 PM
JUDGE ANN POWELLSVP, Human ResourcesMar 10Option Exercise0.002,10702,107Mar 12 04:52 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 10Option Exercise0.006,4100165,472Mar 12 04:50 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 10Option Exercise0.004,878068,910Mar 12 04:51 PM
Caldarella Joseph CSVP & ControllerMar 10Option Exercise0.001,850078,768Mar 12 04:51 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Option Exercise0.0027,6130658,396Mar 12 04:50 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 10Sale55.52100,0005,552,260630,783Mar 10 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 10Sale55.818,799491,0638,861Mar 10 04:43 PM
Schmukler Louis SPres., Global Mfg. & SupplyMar 06Option Exercise0.002,528017,224Mar 10 04:43 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 06Option Exercise0.002,390056,064Mar 10 04:43 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 06Option Exercise0.001,043036,841Mar 10 04:42 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 06Option Exercise0.003,010090,018Mar 10 04:41 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 06Option Exercise0.001,043047,630Mar 10 04:42 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 06Option Exercise0.0029,2400738,383Mar 10 04:40 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 06Option Exercise0.007,3230159,626Mar 10 04:40 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 06Option Exercise0.002,889064,586Mar 10 04:40 PM
Caldarella Joseph CSVP & ControllerMar 06Option Exercise0.001,931077,422Mar 10 04:41 PM
Cuss Francis MEVP & CSOMar 06Option Exercise0.003,0100237,106Mar 10 04:41 PM
Nielsen AnneChief Compliance & Ethics OffMar 06Option Exercise0.00724042,756Mar 10 04:42 PM
CORNELIUS JAMES MDirectorMar 05Sale55.82100,0005,582,000273,393Mar 05 04:40 PM
LEUNG SANDRAGeneral Counsel & SecretaryMar 03Option Exercise0.0099,9370292,758Mar 05 04:38 PM
Moed Samuel JSVP, Strat Plan & AnalysisMar 03Option Exercise0.0015,209040,530Mar 05 04:39 PM
Nielsen AnneChief Compliance & Ethics OffMar 03Option Exercise0.0013,132046,648Mar 05 04:39 PM
Elicker John ESVP Pub Affairs & Inv RelationMar 03Option Exercise0.0017,471051,061Mar 05 04:37 PM
Cuss Francis MEVP & CSOMar 03Option Exercise0.0047,9530254,899Mar 05 04:36 PM
DANIELS BRIANSVP Global Dev & Med AffairsMar 03Option Exercise0.0050,3260103,410Mar 05 04:37 PM
Bancroft Charles AEVP & Chief Financial OfficerMar 03Option Exercise0.00121,0140199,850Mar 05 04:35 PM
Caforio GiovanniEVP & Chief Commercial OfficerMar 03Option Exercise0.0018,875068,527Mar 05 04:36 PM
Caldarella Joseph CSVP & ControllerMar 03Option Exercise0.0031,053089,900Mar 05 04:36 PM
ANDREOTTI LAMBERTOChief Executive OfficerMar 03Option Exercise0.00423,5330912,318Mar 05 04:35 PM
von Autenried PaulSVP, Enterp. Services & CIOMar 03Option Exercise0.0039,420068,820Mar 05 04:40 PM
Schmukler Louis SPres., Global Mfg. & SupplyFeb 28Sale54.496,088331,73614,696Feb 28 04:44 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Option Exercise17.5139,363689,24691,316Feb 25 04:30 PM
Caforio GiovanniEVP & Chief Commercial OfficerFeb 24Sale54.4441,5632,262,63849,753Feb 25 04:30 PM
Elicker John ESVP Pub Affairs & Inv RelationFeb 19Sale54.229,534516,91132,740Feb 19 04:25 PM
Cuss Francis MEVP & CSOFeb 18Option Exercise28.1138,6671,086,929237,037Feb 18 05:07 PM
Cuss Francis MEVP & CSOFeb 18Sale54.6129,8001,627,360207,237Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Option Exercise28.1115,000421,650206,345Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Option Exercise24.0036,251870,038130,266Feb 18 05:07 PM
Bancroft Charles AEVP & Chief Financial OfficerFeb 14Sale54.3552,9632,878,28577,303Feb 18 05:07 PM
LEUNG SANDRAGeneral Counsel & SecretaryFeb 14Sale54.2810,490569,377195,855Feb 18 05:07 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Option Exercise28.11108,0003,035,880586,562Feb 11 04:30 PM
ANDREOTTI LAMBERTOChief Executive OfficerFeb 11Sale52.6686,0754,532,572500,487Feb 11 04:30 PM
Caldarella Joseph CSVP & ControllerFeb 06Option Exercise19.4226,484514,20294,826Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Option Exercise28.1118,750527,06381,989Feb 06 05:29 PM
Caldarella Joseph CSVP & ControllerFeb 06Sale48.9035,4711,734,45759,355Feb 06 05:28 PM
DANIELS BRIANSVP Global Dev & Med AffairsFeb 06Sale48.9328,4401,391,43353,549Feb 06 05:29 PM
CAMPBELL LEWIS BDirectorFeb 05Option Exercise25.702,50064,2502,500Feb 05 05:37 PM
CAMPBELL LEWIS BDirectorFeb 05Sale48.282,500120,7120Feb 05 05:37 PM
CORNELIUS JAMES MDirectorFeb 04Sale48.90100,0004,890,000373,393Feb 04 05:00 PM
Caforio GiovanniEVP & Chief Commercial OfficerJan 03Option Exercise0.007,500054,817Jan 06 05:40 PM
Cuss Francis MEVP & CSONov 02Option Exercise0.006,6660201,827Nov 04 04:20 PM
Schmukler Louis SPres., Global Mfg. & SupplyOct 03Option Exercise0.0013,934025,869Oct 04 04:19 PM
Heller Frances KSVP, Business DevelopmentOct 01Option Exercise0.004,45104,451Oct 02 04:23 PM
CORNELIUS JAMES MDirectorJul 29Option Exercise25.615,000128,025647,383Jul 29 04:44 PM
CORNELIUS JAMES MDirectorJul 29Sale43.815,000219,050642,383Jul 29 04:44 PM
CORNELIUS JAMES MDirectorJul 29Sale43.92100,0004,392,000542,383Jul 30 04:34 PM
von Autenried PaulSVP, Enterp. Services & CIOJun 10Sale47.2425,0001,181,00029,584Jun 12 04:34 PM
Caldarella Joseph CSVP & ControllerJun 06Option Exercise22.1425,000553,50094,617Jun 06 04:31 PM
Caldarella Joseph CSVP & ControllerJun 06Sale46.5326,2751,222,57668,342Jun 06 04:31 PM
Elicker John ESVP Pub Affairs & Inv RelationJun 05Option Exercise20.3933,715687,34868,271Jun 06 04:31 PM
Elicker John ESVP Pub Affairs & Inv RelationJun 05Sale46.3325,9971,204,44142,274Jun 06 04:31 PM
Moed Samuel JSVP, Strat Plan & AnalysisJun 04Option Exercise25.7060,1001,544,27383,585Jun 06 04:31 PM
Moed Samuel JSVP, Strat Plan & AnalysisJun 04Sale47.3858,8982,790,58724,687Jun 06 04:31 PM
ANDREOTTI LAMBERTOChief Executive OfficerJun 04Sale47.74100,0004,774,000478,562Jun 06 04:31 PM
SIGAL ELLIOTEVP, CSO & President R&DJun 03Option Exercise27.0198,8752,670,614231,868Jun 05 04:28 PM
SIGAL ELLIOTEVP, CSO & President R&DJun 03Sale48.1883,6474,030,112148,221Jun 05 04:28 PM
Cazala Beatrice JEVP Commercial OperationsMay 31Sale47.0091,2824,290,254173,375Jun 04 04:18 PM
Caforio GiovanniPres., US PharmaceuticalsMay 31Sale47.0610,538495,91847,316May 31 06:14 PM
SIGAL ELLIOTEVP, CSO & President R&DMay 30Option Exercise26.34170,6254,495,081276,514May 31 06:14 PM
Cazala Beatrice JEVP Commercial OperationsMay 30Sale47.0022,0001,034,000264,657Jun 03 05:56 PM
SIGAL ELLIOTEVP, CSO & President R&DMay 30Sale47.23143,5216,778,497132,993May 31 06:14 PM
Bancroft Charles AEVP & Chief Financial OfficerMay 28Sale48.6825,0001,217,00094,015May 28 04:37 PM
CORNELIUS JAMES MDirectorMay 28Sale47.61100,0004,761,000641,824May 28 04:43 PM
Cazala Beatrice JEVP Commercial OperationsMay 23Option Exercise23.90116,4122,782,247382,657May 23 05:20 PM
Caforio GiovanniPres., US PharmaceuticalsMay 23Option Exercise25.4521,333542,92584,501May 23 05:19 PM
Cazala Beatrice JEVP Commercial OperationsMay 23Sale46.9996,0004,511,040286,657May 23 05:20 PM
Caforio GiovanniPres., US PharmaceuticalsMay 23Sale46.2926,6471,233,49057,854May 23 05:19 PM
CORNELIUS JAMES MDirectorMay 17Option Exercise22.14205,9964,560,751957,820May 20 04:17 PM
CORNELIUS JAMES MDirectorMay 17Sale42.98215,9969,283,708741,824May 20 04:17 PM
CORNELIUS JAMES MDirectorMay 16Sale43.2410,000432,400751,824May 20 04:17 PM
DANIELS BRIANSVP Global Dev & Med AffairsMay 08Sale39.9315,000598,95063,239May 08 04:25 PM
CORNELIUS JAMES MDirectorMay 08Sale39.7810,000397,800761,824May 09 04:19 PM
CORNELIUS JAMES MDirectorMay 07Sale39.9110,000399,100771,824May 09 04:19 PM
ANDREOTTI LAMBERTOChief Executive OfficerMay 04Option Exercise0.0013,9890582,457May 07 06:29 PM
CORNELIUS JAMES MDirectorMay 02Sale39.8510,000398,500781,824May 02 05:01 PM
Moed Samuel JSVP, Strat Plan & AnalysisMay 01Option Exercise0.005,000025,754May 02 04:23 PM
CORNELIUS JAMES MDirectorMay 01Sale39.6610,000396,600791,824May 02 05:01 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 30Option Exercise24.98305,9057,641,575459,398May 01 05:58 PM
SIGAL ELLIOTEVP, CSO & President R&DApr 30Sale39.652,29791,0769,091May 01 05:58 PM